Drug Trial Radar · NCT02914938
A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's Lymphoma
Last checked: Nov 19, 2026Latest source record: May 9, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
97
Actual
Start
Oct 2016
Primary completion
Mar 29, 2023
Study completion Mar 29, 2023
Sponsor
- Lead sponsor
- MEI Pharma, Inc.Industry
- Sponsor type
- Industry
- First posted
- Sep 26, 2016
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Three-Arm Study of ME-401 in Subjects with Relapsed/Refractory CLL/SLL or FL, of ME-401 in Combination with Rituximab in Subjects with Relapsed/Refractory CLL/SLL or B-cell NHL, and of ME-401 in Combination with Zanubrutinib in Subjects with Relapsed/Refractory CLL/SLL or B-cell NHL
Conditions
- Chronic Lymphocytic Leukemia (CLL)
- Small Lymphocytic Lymphoma (SLL)
- Follicular Lymphoma (FL)
- Marginal Zone B Cell Lymphoma
- Diffuse Large B-cell Lymphoma (DLBCL)
- High Grade Non-Hodgkin's Lymphoma
- Mantle Cell Lymphoma (MCL)
Interventions
ME-401Drug
60 mg
RituximabDrug
IV infusion 375 mg/m2
ZanubrutinibDrug
80 and 160 mg bid
Primary outcomes
What the sponsor says the trial is designed to measure.
- Minimum Biologically Effective Dose (mBED) of ME-401 aloneTime frame: 1 year
- Maximally Tolerated Dose (MTD) of ME-401 aloneTime frame: 1 year
- Dose Limiting Toxicities (DLTs) of ME-401 aloneTime frame: within the first 56 days
- Evaluate the safety and tolerability of ME-401 plus rituximabTime frame: 1 year
- Determine the MTD of ME-401 plus zanubrutinibTime frame: 1 year
- Determine the DLTs of ME-401 plus zanubrutinibTime frame: within the first 56 days
- Evaluate the safety and tolerability of ME-401 plus zanubrutinibTime frame: 1 year
Locations
24 sites in 2 countries. Site status is shown where the registry gives one.
University of Arizona
Tucson, Arizona
Compassionate Care
Corona, California
Sylvester Comprehensive Cancer Center (Univ of Miami School of Med)
Miami, Florida
Massachusetts General Hospital Cancer Center
Boston, Massachusetts
Dana Farber
Boston, Massachusetts
Memorial Sloan Kettering
Basking Ridge, New Jersey
Memorial Sloan Kettering
Middletown, New Jersey
Memorial Sloan Kettering
Montvale, New Jersey
Memorial Sloan Kettering
Commack, New York
Memorial Sloan Kettering
Harrison, New York
NYU Langone Laura & Isaac - Perlmutter Cancer Center
New York, New York
Memorial Sloan Kettering Cancer Center
New York, New York
Stony Brook
Stony Brook, New York
Memorial Sloan Kettering
Uniondale, New York
Cleveland Clinic
Cleveland, Ohio
Stephenson Cancer Center
Oklahoma City, Oklahoma
Vanderbilt
Nashville, Tennessee
University of Southwestern Medical Center
Dallas, Texas
MD Anderson Cancer Center
Houston, Texas
Swedish Cancer Institute
Edmonds, Washington
Swedish Cancer Institute
Issaquah, Washington
Swedish Cancer Center
Seattle, Washington
Carbone Cancer Center
Madison, Wisconsin
lstituto Oncologico della Svizzera ltaliana Ospedale Regionale Bellinzona e Valli CH
Bellinzona, Switzerland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.